相关实验视频

Updated: Jul 24, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

针对复发性或耐火性扩散性大B细胞淋巴瘤的抗CD19抗体tafasitamab治疗:一个病例系列

Jianhua You^1,2, Wenting Chen^2,3,4, Zixun Yan¹

¹State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai.

Anti-cancer drugs

|November 2, 2025

概括

塔法西他马布在患有复发性或耐火性扩散性大B细胞淋巴瘤 (R/R DLBCL) 的中国患者中显示出潜力. 这一病例系列表明它耐受性良好,并提供灵活的治疗选择,包括与BTK抑制剂的组合.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 是一种侵略性的非霍奇金淋巴瘤.
复发性或耐火性 (R/R) DLBCL的治疗选择有限.
塔法西他马布是一种抗CD19单克隆抗体,在西方R/R DLBCL群体中显示出有效性.

研究的目的:

报告tafasitamab在中国患者中首次使用的R/R DLBCL.
评估tafasitamab基治疗在这个人群中的疗效和安全性.
探索潜在的治疗策略,包括与其他药物的组合.

主要方法:

四名中国R/R DLBCL患者的病例系列.
患者接受了tafasitamab与lenalidomide联合治疗或单独治疗.
一名患者接受了tafasitamab,lenalidomide和布鲁顿氨酸激酶 (BTK) 抑制剂.

主要成果:

两名患有原发性耐药性疾病的患者在使用tafasitamab和lenalidomide时表现出部分反应或稳定疾病.
一名干细胞移植后复发的患者显示,使用tafasitamab,lenalidomide和BTK抑制剂显著减少了瘤.
一名在二线治疗后复发的患者在tafasitamab单一治疗后实现了完全缓解.
基于tafasitamab的治疗通常耐受良好,中性质减退是最常见的不良事件.

结论:

基于tafasitamab的灵活治疗可能是R/R DLBCL的中国患者的可行选择.
需要进一步研究tafasitamab在中国患者的疗效和安全性.
与诸如BTK抑制剂之类的药物结合使用可能会改善治疗结果.

关键词:

在CD19 mAbAb.这是一个反复的反复的反复.细胞淋巴瘤细胞淋巴瘤复发性或耐火性扩散大B B 塔法西塔马巴巴是什么意思

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

相关概念视频

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.